A new point-of-care viscoelastic testing method to monitor hemostasis in cardiovascular surgical patients is coming to Salem Health Monday, July 10.
The HemoSonics Quantra Hemostasis Analyzer is an FDA-approved analyzer that evaluates and monitors patients for potential hypercoagulable and hypocoagulable conditions. This analyzer provides easy-to-read, actionable results with a fast turnaround time. It will help providers better assess patients during and after cardiovascular surgery for coagulopathies and make the best possible decisions about blood product usage and pharmaceutical intervention.
In addition to helping us better serve our cardiovascular patients, this technology also has FDA approval for use in other clinical settings, such as trauma care.
The HemoSonics Quantra Hemostasis Analyzer goes live on July 10 with the Quantra hemostasis point-of-care testing available in the cardiac operating room and cardiovascular critical care unit (CVCU).
Please join me and our cardiovascular surgeons and physician assistants, cardiovascular anesthesiologists, perfusionists and cardiac operating room/critical care nursing teams, in thanking the following leaders for helping to bring this technology to Salem Health: